eTable 3. Additional Treatment[a] for Treatment Failure or Early/Late Reactivation of Type 1 ROP in Study Eyes

	N	Number (%) Treated after Treatment Failure or Early/Late Reactivation (95% CI)	Relative Risk (95% CI)
Dose of Bevacizumab[b]			
0.250 mg	11	2 (18%) 2% to 52%	ref[c]
0.125 mg	14	4 (29%) 8% to 58%	1.6 (0.3 to 7.1)
0.063 mg	24	8 (33%) 16% to 55%	1.8 (0.5 to 7.3)
0.031 mg	9	0 (0%) 0% to 34%	-
0.016 mg	13	4 (31%) 9% to 61%	1.7 (0.4 to 7.6)
0.008 mg	9	3 (33%) 7% to 70%	1.8 (0.4 to 8.7)
0.004 mg	10	4 (40%) 12% to 74%	2.2 (0.5 to 9.5)
0.002 mg	23	6 (26%) 10% to 48%	1.4 (0.3 to 6.0)
Category of Type 1 ROP at Enrollment			
Zone I, any Stage with Plus Disease	33	8 (24%) 11% to 42%	ref[c]
Zone I, Stage 3 without Plus Disease	19	7 (37%) 16% to 62%	1.6 (0.7 to 3.7)
Zone II, Stage 2 or 3 with Plus Disease	61	16 (26%) 16% to 39%	1.1 (0.5 to 2.4)

CI = confidence interval

[a] Re-treatment (additional treatment following initial intravitreal bevacizumab) included laser retinal photocoagulation or intravitreal bevacizumab at investigator discretion.

[b]Gray text indicates doses that were previously reported ([14]).

[c]This is the reference category. All other groups were compared to this category.